Prothena Corporation plc (PRTA)
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $1.1 per share a year ago.
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago.
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call. My name is Pam, and I will be your coordinator for today.
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.26 per share a year ago.
